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Abstract
Objective. Musculoskeletal US can be useful in monitoring RA. It can be time-consuming and there is no
consensus in defining the joints to evaluate. We assessed the validity, sensitivity to change and feasibility
of a reduced 6-joint US score in patients with RA starting therapy with an anti-TNF agent.
Methods. A group of consecutive RA patients starting etanercept were investigated. The patients
underwent clinical evaluation, laboratory tests and US assessment at baseline and 3 months. A
semi-quantitative score (03) was used to evaluate synovial effusion (SE), synovial proliferation (SP) and
power Doppler (PD) signal in 12 joints. A process of data reduction, based on the frequency of synovial
site involvement by US-SE, US-SP and US-PD signal, was conducted to investigate the validity of a 6-joint
US assessment.
Results. Forty-five RA patients were evaluated. A significant decrease in all clinical, serological and
12-joint US parameters was found at follow-up. A significant correlation between changes in the
DAS-28 and changes in the US scores in the 12-joint assessment was observed at follow-up
(P< 0.001). A reduced 6-joint US score was obtained, including wrist, second MCP and knee joints of
both sides, detecting US-SE in 97.78% of patients, US-SP in 100% of patients and positive US-PD in
100% of patients. The 6-joint US score showed a highly significant correlation with changes in DAS-28
(P< 0.001). The 6-joint evaluation was quick and easy to do.
Conclusion. A 6-joint US assessment may be a valid, sensitive-to-change and feasible method for eval-
uating joint inflammation in RA.
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Introduction
The assessment of joint inflammation is essential in diag-
nosis and in monitoring response to therapies in patients
affected by inflammatory arthropathies, such as RA. For
this purpose, use of musculoskeletal US, with application
of the power Doppler (PD) method, has been increasing
over the past decade, thanks to its high sensitivity for
detecting synovitis [1, 2]. Several studies have
demonstrated the capability of musculoskeletal US in
monitoring response to different biological drugs and in
analysing different joints and synovial recesses [39].
However, there is no evidence regarding which joints
and synovial recesses should be evaluated to assess dis-
ease activity and response to biologic therapy in RA pa-
tients. Nonetheless, a comprehensive evaluation including
multiple recesses of all accessible peripheral joints may
be time consuming in daily practice and clinical trials.
Several studies have evaluated different simplified
scores, showing good correlation with clinical disease
activity indices [35]. Recently Naredo et al. [6] published
a longitudinal study demonstrating the validity, reliability
and sensitivity to change of a 12-joint simplified musculo-
skeletal US assessment compared with a comprehensive
44-joint US evaluation of joint inflammation in RA patients
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starting biological treatment. However, the mean time re-
quired to perform this 12-joint US examination was
22 min, probably still too long to transform US into the
stethoscope for the rheumatologist. Thus the aim of the
present study was to investigate the validity, sensitivity
to change and feasibility of a 6-joint US assessment in
the evaluation of joint inflammation as compared with a
12-joint US examination in patients with established RA
who started treatment with etanercept.
Methods
Patients
In this prospective study we included consecutive pa-
tients affected with RA, diagnosed according to the
1987 ACR criteria [10]. The patients were recruited in the
Rheumatology Unit of the Dipartimento di Medicina
Interna e Specialita` Mediche, Sapienza Universita` di
Roma. All the enrolled patients started therapy with eta-
nercept, an anti-TNF agent, administered according to the
Italian consensus on the use of biologic drugs for the
treatment of RA because of inefficacy or intolerance to
conventional DMARDs. The patients underwent clinical,
laboratory and ultrasonographic evaluation at baseline
before starting biological treatment and after 3 months.
The study was conducted in accordance with the
Declaration of Helsinki and was approved by the local
ethics committee (Comitato Etico Sapienza Universita` di
Roma). Informed consent was obtained from all patients
before entry into the study.
Clinical and laboratory assessment
A single rheumatologist, who was blinded to the US find-
ings, performed the clinical evaluation. Data, including
demographics, date of diagnosis, comorbidities, past
and present treatments, date of the beginning of therapy
with etanercept and concomitant medications, were
recorded on a standardized computerized form. RF
(Behring, Germany; normal values <40 IU/ml) and anti-
cyclic citrullinated protein/peptides antibodies (ACPAs;
normal values <25 IU/ml) (Axis Shield, Dundee,
Scotland) were detected by ELISA following the manufac-
turer’s instructions. For each patient, ESR (mm/h) with the
Westergen method and CRP (mg/dl) were also evaluated.
A count of tender and swollen joints was performed, and a
visual analogue scale (0100 mm) for the patient’s assess-
ment of disease activity was administered. Disease activ-
ity was evaluated by calculating the 28-joint DAS and
response to therapy was assessed according to EULAR
guidelines [11].
Ultrasonographic assessment
Each patient underwent a musculoskeletal US assess-
ment with application of PD. The ultrasonographic evalu-
ation was performed by a single rheumatologist
sonographer, experienced in musculoskeletal US, who
was blinded to the clinical and laboratory findings. A sys-
tematic multiplanar grey-scale and PD examination of
12 joints (elbow, wrist, second MCP, third MCP, knee
and ankle of both sides) was performed using a MyLab
70 XVisionGold (Esaote, Firenze, Italy) machine equipped
with a multifrequency linear array transducer (618 MHz).
B-mode frequency ranged from 12 to 18 MHz (12 MHz for
elbow, knee and ankle assessment, 15 MHz for wrist and
18 MHz for second and third MCP); PD pulse repetition
frequency was 750 Hz; Doppler frequency was
6.711.1 MHz; low wall filters were used. At the beginning
of each scanning session at different sites, focus was pos-
itioned at the level of the region of interest. Colour gain
was adjusted just below the degree that caused the ap-
pearance of noise artefacts. The colour box was pos-
itioned at the level of the assessed site, enlarging the
box to the upper part of the image.
The US assessment included 24 synovial sites in
12 joints: elbow (anterior and posterior recesses), wrist
(dorsal carpal recesses), second and third MCP (dorsal
side, palmar side), knee (suprapatellar recess, lateral
parapatellar recess) and ankle (anterior tibiotalar recess,
medial tibiotalar recess, lateral tibiotalar recess). These
joints and synovial sites were chosen from the simplified
12-joint score previously described by Naredo et al. [6].
We then considered each joint as a unique structure,
and we assessed the presence of synovial effusion (SE)
and synovial proliferation (SP) by B-mode US and PD
within the SP in each joint. According to the OMERACT
definitions [12], SE and SP were defined as follows: SE as
an abnormal hypoechoic or anechoic IA material that is
displaceable and compressible, but does not exhibit PD
signal; SP as an abnormal hypoechoic IA tissue that is
non-displaceable and poorly compressible and may
exhibit PD signal.
US-detected elementary lesions (US-SE, US-SP and
US-PD) were scored according to a semi-quantitative
scale (0 = absent, 1 = mild, 2 = moderate and 3 = severe).
The higher score obtained for each of the US elementary
lesions (US-SE, US-SP and US-PD) at each synovial site
was then considered for the scoring of each joint as a
unique structure.
Fig. 1 shows representative images of the four different
degrees of US-SE in the anterior recess of the knee. Thus
each of the 12 joints had a US score resulting from the
sum of US-SE, US-SP and US-PD scores ranging from
0 to 9. Finally, from the sum of the scores at all joint
sites, we obtained a US-total 12-joint score (ranging
from 0 to 108).
Statistical analysis
Statistical analysis was performed using SPSS statistical
software, version 13.0 (SPSS, Chicago, IL, USA).
Quantitative variables (DAS-28, US parameters) were
given as the mean (S.D.) and range. Comparisons between
groups were performed using contingency tables and
Pearson’s 2. Corrections were made where necessary
for the sample size (Fisher’s exact test). The comparisons
between parametric variables were performed with
the Wilcoxon’s test. One-way analysis of variance was
applied to evaluate the comparisons between multiple
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groups. Pearson’s and Spearman’s tests were used to
perform the correlation analysis.
As a first step, we undertook a process of data reduc-
tion based on the frequency of joint involvement within the
12 joints by US-SE, US-SP and US-PD signal at baseline.
A reduced US assessment was selected from different
joint combinations. The reduced model was chosen con-
sidering that the joints selected should have allowed us to
detect >97% of the joints involved by US-SE, US-SP and
US-PD signal. The final identified model was named
reduced US assessment. US-detected elementary lesions
(US-SE, US-SP and US-PD) were scored for the reduced
US assessment by the same method used for scoring the
12 joints, thus obtaining a reduced US count.
Afterwards, the sonographer was asked to record the
time taken to perform the 12-joint US assessment and the
reduced US assessment in two consecutive patients with
RA. Content validity was evaluated by correlating the
12-joint US count (including US-SE, US-SP and US-PD
scores) with the total reduced US count (obtained with
the reduced US assessment) using Pearson’s rank correl-
ation coefficient. Construct validity was evaluated by test-
ing the association between the 12-joint US count, the
reduced US count and the EULAR response, and by
correlating the 12-joint US count, the reduced US assess-
ment count and the disease activity index (DAS-28) using
Pearson’s correlation coefficient. Sensitivity to change
of the US variables was tested by comparing the mean
change in reduced US assessment from baseline to
3 months; in addition, we evaluated the correlation be-
tween the changes in the reduced US assessment and
the variations in DAS-28 from baseline to 3 months.
The feasibility of the reduced US assessment was esti-
mated by comparing the time spent on the 12-joint US
examination and the reduced US assessment by the
independent-samples t-test. P-values <0.05 were
considered statistically significant.
Results
Forty-five Caucasian patients (8 males and 37 females)
were included in the study. The main demographic, clin-
ical and laboratory parameters of the enrolled patients at
baseline and after 3 months of etanercept treatment are
reported in Table 1.
Clinical and laboratory features
The disease activity was moderate to severe in all patients
at baseline [mean DAS-28 (S.D.) 4.5 (1.2)]. After 3 months
of therapy with etanercept, a good to moderate response,
according to EULAR criteria was registered in 14 of the
45 patients (31.1%; good response in 7 of the 45, and
moderate in 7 of the 45). A significant decrease in clinical
and laboratory parameters was found at 3 months
follow-up. DAS-28 was reduced to 3.6 (1.3) (P= 0.0016),
ESR decreased from 27.1 (20.3) to 23.5 (21.2) mm/h
(P< 0.001) and CRP decreased from 10.5 (18.7) to 8.6
(10.6) mg/dl (P< 0.001).
12-joint US assessment
US-SE, US-SP and US-PD values assessed at 12 joints at
baseline and 3 months are reported in Table 2. All the
FIG. 1 Representative images of the four different degrees of US-SE in the anterior recess of the knee. Clockwise from
upper left: (a) normal knee, grade = 0; (b) mild effusion, grade = 1; (c) moderate effusion, grade = 2; and (d) severe effusion,
grade = 3. p: patella; t: tendon; f: femur; *: synovial effusion.
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scores were significantly reduced after 3 months of
anti-TNF therapy (P< 0.001 for all parameters).
Six-joint US assessment
We obtained a reduced 6-joint US model after adoption
of different models, as shown in Table 3. At first, we
screened the single joints from the 12-joint assessment
and found that US-SE, US-SP and US-PD were mostly
present at the wrist, knee and second MCP joints.
Among these joints, the one with the highest prevalence
of abnormalities was the wrist. Thus we assumed this joint
to be the reference joint and then each of the remaining
joints was added to the count. We found that adding the
data from the knee assessment allowed us to obtain a
very high sensitivity, although lower than the requested
97% for each the three parameters. Thus we added the
US data on each of the remaining joints to the count and
found that the highest sensitivity was reached when
the US data from the second MCP joint were added.
We thus obtained a 6-joint US assessment that was
able to detect 97.7% of patients with 12-joint US-SE,
100% of patients with 12-joint US-SP and 100% of
those with 12-joint PD.
Correlation between the 12-joint and the 6-joint US
assessment
The 12-joint US count decreased from 20.87 (16.86) at
baseline to 13.67 (10.62) (P< 0.001). The 12-joint US vari-
ables significantly correlated with the 6-joint US variables
both at baseline and at the 3-month follow-up. All the
variables (12-joint US-SE, US-SP and US-PD) showed a
positive correlation with the respective 6-joint variables
(P< 0.0001 for all comparisons) at baseline. The 12-joint
US count at baseline showed a positive correlation with
the 6-joint US total count (P= 1.071022, R= 0.943,
Fig. 2). Also, the 12-joint US count at 3 months positively
correlated with the 6-joint US count at the same time point
(P= 2.7 1019, R= 0.918).
Correlation between the 12-joint US assessment, the
6-joint US assessment and the clinical features
The 12-joint US count at baseline positively correlated
with CRP at baseline (P= 0.005, R= 0.461). Changes in
the 12-joint US count showed a positive correlation with
changes in DAS-28 (P= 0.047, R= 0.338). When consider-
ing the changes in the US-SE, US-SP and US-PD in 12
joints, only US-SP correlated with changes in DAS-28
(P< 0.05, R= 0.339).
The 6-joint US count decreased from 14.80 (12.1) at
baseline to 10.00 (7.5) (P= 0.0037, Table 2) and showed
TABLE 1 Clinical features of the 45 RA patients studied at baseline and after 3 months of etanercept
therapy
Feature Baseline 3 months P-values
Age, mean (S.D.), months 638.5 (173.4)
Disease duration, mean (S.D.), months 120.7 (98.7)
Male/female 8/37
Smoke, n (%) 7 (15.5)
Concomitant MTX, n (%) 10 (22.2)
Anti-TNF monotherapy, n (%) 10 (22.2)
Prednisone (PDN) equivalent, mean (S.D.), mg/day 7.1 (6.2)
ESR, mean (S.D.), mm/h 27.1 (20.3) 23.5 (21.2) <0.001
CRP, mean (S.D.), mg/dl 10.5 (18.7) 8.6 (10.6) <0.001
RF, mean (S.D.), U/l 240.1 (264.6) (range 9.4600) 192.1 (240.0) NS
ACPA, mean (S.D.), U/l 70.7 (46) (range 9121) 64.8 (43.8) NS
DAS-28, mean (S.D.) 4.5 (1.2) 3.6 (1.3) 0.0016
EULAR response,a n (%) — 14 (31.1)
aGood or moderate response.
TABLE 2 Baseline and 3 months values of US-SE, US-SP
and US-PD for the 12- and the 6-joint US assessment
Baseline,
mean (S.D.)
After
3 months,
mean (S.D.) P-values
US-SE 12 joints
range (036)
8.71 (6.23) 5.84 (4.05) <0.001
US-SP 12 joints
(036)
8.27 (6.14) 5.47 (4.06) <0.001
US-PD 12 joints
(036)
4.36 (5.44) 2.67 (3.38) <0.001
US 12 joints count
(0108)
20.87 (16.86) 13.67 (10.62) <0.001
US-SE 6 joints
(018)
5.71 (3.92) 4.00 (2.59) <0.001
US-SP 6 joints
(018)
5.80 (4.21) 4.07 (2.82) <0.001
US-PD 6 joints
(018)
3.62 (4.35) 2.16 (2.69) <0.001
US 6 joints count
(054)
14.80 (12.1) 10.00 (7.5) 0.0037
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positive correlation with DAS-28 at baseline (P= 0.002,
R= 0.535, Fig. 3), as well as with CRP at the same time
point (P= 0.001, R= 0.519).
Feasibility
There was a significant difference between the mean time
spent on the 12-joint US examination [23.4 (2.6) min] and
the mean time spent on the 6-joint US examination [14.1
(3) min, P< 0.001].
Discussion
Our results provide evidence that a 6-joint US assessment
of joint inflammation may be a valid, sensitive-to-change
and feasible method for monitoring the response to eta-
nercept therapy in patients affected with RA. In the last
decade, several studies have demonstrated that US as-
sessment can be useful in the management of RA and in
monitoring the course of the disease at all stages [1]. The
application of US is helpful in the evaluation of RA patients
and represents a complementary tool to classic methods
used to detect inflammatory status, such as clinical evalu-
ation and radiography, particularly when MCP, PIP and
MTP joints are considered [1315].
Short-term follow-up studies have widely demonstrated
the correlation between disease activity and degree of
inflammation of synovial tissue, as shown by grey-scale
and US-PD evaluation [1618]. US can be used in the
evaluation of response to biological drugs, such as TNF
antagonists. It was demonstrated that the effective admin-
istration of TNF blocking agents results in a significant
decrease in vascularization assessed with US. For
instance, Naredo et al. [7] found a significant parallel
improvement in DAS-28 and US parameters in RA
patients undergoing therapy with a TNF blocking agent.
The authors suggested that US evaluation with application
of PD could be a valid method for monitoring response to
anti-TNF therapy in RA patients.
However, there is no evidence regarding which joints
and synovial recesses are appropriate for studying and
monitoring RA patients by means of US. Nonetheless, a
remarkable variability in the synovial sites assessed can
be observed in published studies. An appropriate choice
FIG. 2 Correlation between the 12-joint US count and the
6-joint US count at baseline (P= 1.07 1022, R= 0.943).
FIG. 3 Correlation between the 6-joint US count and the
DAS-28 at baseline (P= 0.002, R= 0.535).
TABLE 3 Sensitivity for detecting US-SE, US-SP and
US-PD of the combination of joints selected for the
reduced US assessment
US 12 joints
US-SE
(n=45)
US-SP
(n=45)
US-PD
(n=45)
Wrist, n (%) 43/45 (95.5) 42/45 (93.3) 42/45 (93.3)
Second MCP,
n (%)
30/45 (66.7) 27/45 (60) 20/45 (44.4)
Third MCP,
n (%)
18/45 (17.8) 16/45 (35.5) 19/45 (42.2)
Elbow, n (%) 15/45 (33.3) 9/45 (20) 13/45 (28.9)
Knee, n (%) 33/45 (73.3) 32/45 (71.1) 25/45 (55.5)
Ankle, n (%) 22/45 (48.9) 20/45 (44.4) 22/45 (48.9)
Wrist + knee,
n (%)
44/45 (97.7) 43/45 (95.5) 44/45 (97.7)
Wrist + knee +
second
MCP, n (%)
44/45 (97.7) 45/45 (100) 45/45 (100)
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of the joints to be assessed is fundamental. It is necessary
to identify those joints that can be considered sensitive
to represent the patient global inflammatory status.
However, a comprensive evaluation of all accessible
joints is time consuming. On the other hand, assessing
only the swollen or tender joints can lead to a lack of in-
formation due to the subjectivity of the examination and
the possibility of the presence of subclinical inflammation.
For these reasons, US assessment for clinical practice
must result from a compromise between an extensive
and an informative report. Nonetheless, standardization
of the US technique will allow comparison between
groups of RA patients and, analogous to DAS-28, may
result in important clinical trials. Several authors have
faced the problem with different approaches and results.
Two studies adopted the joints present in several dis-
ease activity indices for US assessement. Hammer et al.
[9] suggested a 78-joint US assessment. They evaluated
20 RA patients starting adalimumab as the first biological
agent and found an association between US scores and
clinical and laboratory parameters [9]. US detected higher
numbers of inflamed joints when compared with clinical
assessment. However, the average time spent for each
US examination of all 78 joints was about 70 min, thus it
is not compatible with daily clinical practice [9].
Dougados et al. [8] conducted a multicentre study on
RA patients requiring TNF blocker. US evaluation was per-
formed in the joints included in the DAS-28, plus the MTP
joints. Three different US scoring systems using a range of
joint counts [20] were analysed using either a binary (yes/
no) or a semi-quantitative score (03). The MTP joints
evaluation was added because of their frequent involve-
ment in the early phases of the disease. The authors found
that US evaluation of synovitis could represent an out-
come measure at least as good as, and possibly more
accurate than, physical examination. The time spent by
investigators in collecting the US data ranged from 10 to
25 min, depending on the number of joints evaluated, thus
it was satisfactory for patient acceptance [8]. However,
this short time (relative to the number of joints assessed)
was the main concern with this study. Indeed, most of the
studies present in the literature, and our study as well,
reported a longer time needed for US examination.
Several authors arbitrarily selected the joints to be eval-
uated with US. This selection was generally performed on
the basis of the most frequent involvement in RA found in
the clinical data. In our experience, we have previously
evaluated the response to treatment with etanercept and
adalimumab by choosing the second and fifth MCP, the
third PIP, the wrist and the knee joints [3, 4]. The US score
applied in those studies showed a significant decrease
after a long-term follow-up (24 months in patients treated
with adalimumab and 12 months in those treated with
etanercept) and a significant correlation with disease
activity (DAS-28) [3, 4]. In 2009, Backhaus et al. [5] used
a novel US score using the wrist, the second and third
MCP, the second and third PIP, and the second and
fifth MTP joints of the clinically dominant side of RA pa-
tients, the so-called US7 score. In this study, a significant
correlation between changes in the US parameters for
synovitis and the DAS-28 was registered. This US7
score may represent a valuable tool for US examination
of inflamed joint activity in rheumatological diseases, es-
pecially in RA. Concentration on a small number of active
joint regions reduced examination time (1020 min), sug-
gesting the possibility of integrating the US7 score in daily
rheumatological practice [5]. However, possible limita-
tions could have been that only one side of the body
was assessed, thus possibly excluding a number of
active patients with RA.
Naredo and colleagues [6] performed one of the more
interesting studies. The authors chose the joints to be
evaluated by a process of data reduction starting from
the 44 joints included in the DAS-44 index. Afterwards,
they evaluated the frequency of involvement of synovial
sites by both synovitis and PD signal and then obtained a
simplified assessment evaluating 12 joints. The results
showed that this 12-joint US score correlated with the
non-simplified 44-joint US score. This simplified US
assessment thus showed content and construct validity.
Considering the feasibility, there was a significant differ-
ence between the mean time spent on the 44-joint US
examination (83.6 min) and the mean time spent on the
12-joint US examination (22 min) [6].
Starting from this study, we thought that 22 min could
still represent a long time expense that cannot be afforded
in daily clinical practice as well as in clinical trials. Thus,
applying the same process of data reduction used by
Naredo et al. [6], we aimed to investigate the validity,
responsiveness and feasibility of a 6-joint US score in as-
sessing joint inflammation as compared with the already
described 12-joint US evaluation.
Our 6-joint US assessment detected 97.7% of patients
with 12-joint US-SE, 100% of patients with 12-joint US-SP
and 100% of 12-joint PD. These percentages indicate that
evaluation of the six selected joints was very sensitive.
Our 6-joint US score showed a significant correlation
with DAS-28, thus showing it to be at least as sensitive
as the clinical data. Importantly, the score was sensitive to
change after 3 months of follow-up of anti-TNF therapy,
suggesting that the score can be used in the short-term
monitoring of the response to anti-TNF treatment.
We evaluated patients treated with anti-TNF due to the
intrinsic features of these drugs in influencing joint inflam-
mation and the specific features of patients naı¨ve to
anti-TNF who have high disease activity indexes and
amelioration of symptoms is expected in a significant
percentage of patients and a relatively short period of
time. Nonetheless, US can also recognize subclinical
synovitis in RA patients treated with DMARDS, as shown
by Brown et al. [19]. When considering the usage of US
scoring systems in the follow-up of patients with RA,
Backhaus et al. [5] used the German US7 in patients trea-
ted with DMARDs, anti-TNF or a combination of the two.
More recently, Saleem et al. [20] used US in the assess-
ment of remission in RA. They evaluated patients treated
with either DMARDs or a combination of TNF blockers
and MTX, showing that US is superior to clinical
www.rheumatology.oxfordjournals.org 871
Six-joint US assessment in RA
 at U
N
IV
ERSITA
 STU
D
I LA
 SA
PIEN
ZA
 on O
ctober 29, 2016
http://rheum
atology.oxfordjournals.org/
D
ow
nloaded from
 
evaluation. Indeed, the clinical criteria may underestimate
the detection of low but clinically relevant levels of
inFammation.
Finally, Peluso et al. [21] showed that US-PD can be
used in the assessment of remission in patients with
early RA as well as in those with long-standing RA, inde-
pendently of the use of DMARDs (specifically MTX) and/or
anti-TNF.
In conclusion, the application of US assessment in clin-
ical practice should include a comprehensive evaluation
of patient inflammatory status and feasibility in order to
reduce the time needed for the US examination. The
importance of testing the feasibility of US was included
in the research agenda of the OMERACT US task force in
2009, being a fundamental aspect of the OMERACT filter
[22]. In our study, we achieved a significantly shorter
time of execution, suggesting that this 6-joint model
could be more feasible than others previously described.
Rheumatology key messages
. A comprehensive US evaluation of inflammation in
RA is time consuming.
. The 6-joint US assessment was able to detect
synovitis in 100% of patients evaluated with the
12-joint assessment.
. US assessment of wrists, second MCP and knees
is valid, sensitive to change and feasible in the
evaluation of RA synovitis.
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